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Summary
Disease characteristics.  Trimethylaminuria is characterized by a fishy odor resembling that
of rotten or decaying fish that results from excess excretion of trimethylamine in the urine,
breath, sweat, and reproductive fluids. No physical symptoms are associated with
trimethylaminuria. Affected individuals appear normal and healthy; however, the unpleasant
odor often results in social and psychological problems. Symptoms are usually present from
birth and may worsen during puberty. In females, symptoms are more severe just before and
during menstruation, after taking oral contraceptives, and around the time of menopause.
Diagnosis/testing.  Diagnosis of trimethylaminuria is based on either the percent of total
trimethylamine (free trimethylamine [TMA] plus the non-odorous metabolite TMA N-oxide)
excreted in the urine as unmetabolized free TMA or the concentration of unmetabolized TMA
in the urine. FMO3 is the only gene known to be associated with trimethylaminuria. Sequence
analysis is available clinically.
Management.  Treatment of manifestations: dietary restriction of: (1) trimethylamine (present
in milk obtained from wheat-fed cows) and its precursors including choline (present in eggs,
liver, kidney, peas, beans, peanuts, soya products, and brassicas [Brussels sprouts, broccoli,
cabbage, cauliflower]), lecithin and lecithin-containing fish oil supplements, (2)
trimethylamine N-oxide (present in seafood [fish, cephalopods, and crustaceans]), (3)
inhibitors of FMO3 enzyme activity such as indoles (found in brassicas); use of acid soaps and
body lotions to remove secreted trimethylamine by washing; use of activated charcoal and
copper chlorophyllin to sequester trimethylamine produced in the gut; antibiotics
(metronidazole, amoxicillin, and neomycin) to suppress production of trimethylamine by
reducing bacteria in the gut; laxatives (e.g., lactulose) to decrease intestinal transit time;
riboflavin supplements to enhance residual FMO3 enzyme activity. Prevention of primary
manifestations: See Treatment of manifestations.Prevention of secondary complications:
planning and monitoring of diet to ensure that the daily intake of choline and folate meets
recommendations for age and sex; no restriction of dietary choline during pregnancy and
lactation. Agents/circumstances to avoid: foods with a high content of precursors of
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trimethylamine or inhibitors of FMO3 enzyme activity (seafoods: fish, cephalopods, and
crustaceans), eggs, offal, legumes, brassicas, and soya products; food supplements and "health"
foods that contain high doses of choline and lecithin; drugs metabolized by the FMO3 enzyme;
circumstances that promote sweating (exercise, stress, and emotional upsets). Testing of
relatives at risk: biochemical testing of sibs to identify those who are affected and will benefit
from management to reduce production of trimethylamine.
Genetic counseling.  Trimethylaminuria is inherited in an autosomal recessive manner. The
parents of an affected individual are obligate heterozygotes and therefore carry one mutant
allele. Heterozygotes (carriers) are asymptomatic. At conception, each sib of an affected
individual has a 25% chance of being affected, a 50% chance of being an asymptomatic carrier,
and a 25% chance of being unaffected and not a carrier. No laboratories offering molecular
genetic testing for prenatal diagnosis of trimethylaminuria are listed in the GeneTests
Laboratory Directory; however, prenatal testing may be available through laboratories offering
custom prenatal testing for families in which the disease-causing mutations have been
identified.
Diagnosis
Clinical Diagnosis
Trimethylaminuria may present with a body odor resembling that of rotten or decaying fish.
Diagnosis of trimethylaminuria has been discussed in detail [Cashman et al 2003] and "best-
practice" diagnostic guidelines have been summarized [Chalmers et al 2006].
Diagnosis based on the sense of smell of the examiner is complicated by the following:
• The presence of the odor is often episodic and thus may not be noticeable when the
person is examined.
• The human nose is normally very sensitive to trimethylamine, with some individuals
being able to detect concentrations as low as 1 part in 109; however, olfactory testing
is subjective and some people are unable to detect the smell of trimethylamine.
• The odor may be caused by compounds other than trimethylamine.
Testing
Metabolism of trimethylamine is primarily via N-oxygenation, catalyzed by the enzyme flavin-
containing monooxygenase 3 (FMO3).
Biochemical testing.  Trimethylaminuria is characterized by excretion of excessive amounts
of unoxidized trimethylamine in the urine, breath, sweat, and reproductive fluids.
Trimethylamine is extremely volatile and has a pungent ammoniacal odor reminiscent of
rotting fish. For laboratories offering biochemical testing see .
Diagnosis of trimethylaminuria is based on one of the following:
• Percent of total trimethylamine (TMA) (i.e., free TMA plus the non-odorous
metabolite TMA N-oxide) excreted in the urine as unmetabolized free TMA
– Severe trimethylaminuria: less than 40% of total TMA excreted as
unmetabolized free TMA
– Mild trimethylaminuria: 10%-39% of total TMA excreted as unmetabolized
free TMA
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– Unaffected: 0%-9% of total TMA excreted as unmetabolized free TMA
• Concentration of unmetabolized TMA in the urine.  A urinary concentration of
free TMA of 10µg/mL (18-20 µmol/mmol creatinine) or higher, correlating with a
urinary output of TMA of about 15 to 20 mg/day, appears to represent a threshold for
the presence of the fishy body odor associated with the disorder [Mitchell & Smith
2001].
Note: (1) Some forms of trimethylaminuria are transient or episodic; to distinguish them from
the primary inherited form, biochemical testing should be performed on two separate occasions.
(2) Choline challenge. It may also help to carry out the biochemical testing after an oral
challenge of choline bitartrate (2.5 to 15g, depending on age) [Chalmers et al 2006]. Although
this level of choline challenge is generally well tolerated, one individual developed an adverse
reaction, with fever and vomiting [Chalmers et al 2006]. (3) Because unaffected women may
have a short episode of trimethylaminuria at the onset of and during menstruation, females
should not be tested during this time frame.
The methods of detecting TMA and TMA N-oxide in urine currently available involve
sophisticated equipment and require skilled and experienced personnel:
• Head-space gas chromatography (GC) or GC-mass spectrometry [Mills et al
1999]. Disadvantages: GC techniques are time consuming, TMA N-oxide must be
chemically reduced to TMA before analysis, and both TMA and TMA produced by
reduction of TMA N-oxide must be extracted from urine.
• Mass spectroscopy (MS)* including fast atom bombardment MS (FAB-MS) [Mamer
et al 1999], direct infusion electrospray MS [Cashman et al 2001], or matrix-assisted
laser desorption/ionization time-of-flight MS (MALDI-TOFMS) [Hsu et al 2007]
• Proton nuclear magnetic resonance (NMR) spectroscopy* [Maschke et al 1997,
Murphy et al 2000, Podadera et al 2005, Lee et al 2006]
* MS and proton NMR have the advantage of being able to detect TMA and TMA N-oxide
simultaneously with great sensitivity. NMR has the further advantage of requiring no prior
extraction or separation of metabolites and thus measurement can be done directly on urine
samples.
Heterozygotes
• Under normal dietary conditions heterozygotes (carriers) and unaffected individuals
excrete less than 10% of total TMA as the unmetabolized free amine and thus cannot
be distinguished.
• TMA challenge.  Carriers can be detected using a "TMA load" test in which 600 mg
of TMA is given orally in a gelatin capsule. After the TMA load test, carriers excrete
20%-30% of total TMA as the free unmetabolized amine, whereas unaffected
individuals excrete less than 13% of total TMA as the free unmetabolized amine
[Mitchell & Smith 2001].
Molecular Genetic Testing—GeneReviews designates a molecular genetic test as
clinically available only if the test is listed in the GeneTests Laboratory Directory by either a
US CLIA-licensed laboratory or a non-US clinical laboratory. GeneTests does not verify
laboratory-submitted information or warrant any aspect of a laboratory's licensure or
performance. Clinicians must communicate directly with the laboratories to verify
information. —ED.
Gene.   FMO3 is the only gene known to be associated with trimethylaminuria.
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Clinical testing
• Sequence analysis.  It is estimated that 99% of FMO3 mutations may be detected by
sequence analysis. Insufficient studies have been published to establish the mutation
detection frequency.
Table 1 summarizes molecular genetic testing for this disorder.
Table 1. Molecular Genetic Testing Used in Trimethylaminuria
Test Method Mutations Detected Mutation Detection Frequency by Test Method Test Availability
Sequence analysis FMO3 sequence variants ~99%  1 Clinical 
1. Insufficient studies have been published to establish the actual mutation detection frequency.
Interpretation of test results.  For issues to consider in interpretation of sequence analysis
results, click here.
Testing Strategy
Establishing the diagnosis in a proband.  Individuals complaining of or exhibiting a fishy
odor should be tested for urinary excretion of TMA, ideally on two separate occasions. Testing
can be done under normal dietary conditions or following a choline challenge.
Note: The choline challenge described in Testing can help confirm TMA in affected
individuals. The choline challenge does not distinguish between carriers and unaffected
individuals.
If an individual excretes more than 10% of total TMA as the free amine under normal dietary
conditions, sequence analysis should be offered.
• If an individual is found to be homozygous or compound heterozygous for known
loss-of-function mutations of FMO3, the diagnosis is confirmed.
• If novel mutations are found, it is important to establish that:
1 The mutations are not relatively common in the general population, i.e.,
polymorphic variants;
2 They cosegregate with the disorder in the family;
3 They abolish (or substantially reduce) the ability of FMO3 to catalyze N-
oxygenation of TMA, as assessed by assaying heterologously expressed
mutant protein.
Carrier testing for at-risk relatives.  Carriers can be distinguished from unaffected
individuals with the TMA challenge described in Testing: Heterozygotes.
Genetically Related (Allelic) Disorders
No other phenotypes are known to be associated with mutations in the FMO3 gene.
Clinical Description
Natural History
Trimethylaminuria is characterized by fishy odor resulting from excess excretion of
trimethylamine in the urine, breath, sweat, and reproductive fluids.
The trimethylamine is derived from dietary precursors, such as choline and trimethylamine
N-oxide, via the action of bacteria in the gut. It is normally metabolized in the liver by the
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enzyme FMO3 to produce trimethylamine N-oxide, which is non-volatile and non-odorous.
Excess trimethylamine results from a mismatch between the ability of the enzyme FMO3 to
catalyze the N-oxygenation of trimethylamine and the amount of substrate.
Two types of trimethylaminuria exist, resulting from one of the following:
• Decrease in the amount or activity of the enzyme FMO3, resulting from either
genetic factors (mutations in the FMO3 gene), physiologic factors (hormone levels),
or environmental factors (presence of inhibitory chemicals). This type of
trimethylaminuria is characterized by a high urinary TMA/TMA N-oxide ratio.
• Substrate overload of FMO3 enzyme activity resulting from either an excess of
dietary precursors of TMA or variations in gut fauna, causing increased release of
TMA. This type of trimethylaminuria is characterized by a high concentration of TMA
in the urine, but a normal urinary TMA/TMA N-oxide ratio.
The two types of trimethylaminuria are intimately interrelated: a combination of genetic,
physiologic, and environmental factors may interact to give rise to the disorder. For instance,
a substrate load that is handled by one individual may represent a substrate overload for a
person whose FMO3 enzyme activity is decreased.
No physical symptoms are associated with trimethylaminuria; affected individuals appear
normal and healthy. However, the unpleasant odor characteristic of the disorder often results
in social and psychological problems [Mitchell & Smith 2001] and can have serious effects on
personal and working lives. These may include the following:
• In childhood, being shunned, ridiculed, or bullied at school, leading to aggressive or
disruptive behavior and poor educational performance
• A sense of shame or embarrassment, leading to low self-esteem and reluctance to seek
medical help
• Avoidance of contact with people, leading to social isolation, loneliness, frustration,
and depression
• Difficulties in initiating or maintaining relationships
• In extreme cases, paranoid behavior, desperation, and suicidal tendencies
The enzyme FMO3 is also involved in the metabolism of various therapeutic drugs. Affected
individuals exhibit abnormal metabolism of the nonsteroidal anti-inflammatory benzydamine
[Mayatepek et al 2004]. Anecdotal evidence suggests that the metabolism of other drugs that
are substrates of the enzyme FMO3 may also be affected.
Dysfunctional metabolism of endogenous amines such as tyramine that are substrates of the
enzyme FMO3 may contribute to the depression seen in some persons.
For individuals with primary genetic trimethylaminuria, symptoms are usually present from
birth. The condition may worsen during puberty. In females, symptoms are more severe just
before and during menstruation, after taking oral contraceptives, and around menopause,
probably because of a decrease in expression of the FMO3 gene in response to steroid
hormones.
Treatment and dietary management may alleviate symptoms in some, but not all individuals.
Other.   Historical references to individuals who appear to have had trimethylaminuria include
the description of Satyavati, a young woman who smelled of rotting fish, in the Mahabharata,
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the Indian epic of the Bharata Dynasty compiled in about AD 400, and Trinculo's description
of Caliban ("he smells like a fish") in Shakespeare's The Tempest.
Genotype-Phenotype Correlations
On a normal diet, individuals who are homozygous or compound heterozygous for loss-of-
function FMO3 mutations secrete more than 40% of total TMA as the free unmetabolized
amine and consequently have a fishy odor.
Several nonsense or missense mutations that essentially abolish the ability of the FMO3
enzyme to catalyze N-oxygenation of TMA have been identified. In general, the greater the
effect of the mutation on the FMO3 enzyme activity the more severe the symptoms and the
less responsive to treatment.
More common normal variants have little or no effect on enzyme activity; however,
combinations of variants (e.g., p.Glu158Lys and p.Glu308Gly) in cis configuration (i.e., on
the same chromosome), may cause "mild" trimethylaminuria, resulting in the excretion of
10%-39% of total TMA as the free unmetabolized amine.
Nomenclature
Trimethylaminuria has been described as fish-odor syndrome, fish malodor syndrome, and
stale fish syndrome.
Prevalence
The incidence of heterozygous carriers in the white British population is 0.5% to 1.0%. It is
higher in other ethnic groups studied: 1.7% in Jordanian, 3.8% in Ecuadorian, and 11.0% in
New Guinea [Mitchell et al 1997].
Differential Diagnosis
For current information on availability of genetic testing for disorders included in this section,
see GeneTests Laboratory Directory. —ED.
A classification scheme for trimethylaminuria has been proposed [Mitchell & Smith 2001,
Mitchell 2005].
• Primary genetic trimethylaminuria.  Caused by FMO3 mutations that result in loss
of function of FMO3 enzyme activity, this subtype accounts for the majority of
reported cases. Combinations of certain FMO3 polymorphisms may cause a less
severe form of the condition.
• Acquired trimethylaminuria emerges during adult life as a consequence of hepatitis
in individuals with no previous personal history or familial history of the disorder.
The metabolic changes persist after the liver problems have resolved, suggesting a
permanent change in the expression or activity of the FMO3 enzyme.
• Transient childhood trimethylaminuria has been reported in preterm infants fed a
choline-containing infant formula. Symptoms disappear as the children mature or
when the choline source is discontinued [Pardini & Sapien 2003]. Young children
who are heterozygous for a loss-of-function mutation of FMO3 or have certain
combinations of FMO3 polymorphisms may exhibit mild symptoms of the disorder
[Mayatepek & Kohlmuller 1998, Zschocke et al 1999]. Transient childhood forms
are a consequence of the immaturity of FMO3 expression, which is switched on after
birth and continues to increase throughout childhood.
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• Transient trimethylaminuria associated with menstruation.  A short episode of
trimethylaminuria can occur in women during menstruation [Mitchell & Smith
2001, Shimizu et al 2007]. The effect is more pronounced in women homozygous for
polymorphic variants that result in a limited decrease in FMO3 enzyme activity
[Shimizu et al 2007].
• Precursor overload can cause a transient form of trimethylaminuria that results from
saturation of the enzyme FMO3. It can occur in individuals with Huntington disease
or Alzheimer disease who have been given large oral therapeutic doses of choline (up
to 20g per day).
• Disease states
– Liver cirrhosis, impaired hepatocellular function, or the existence of
portosystemic shunts may affect clearance of TMA absorbed from the gut.
The resulting trimethylaminuria may contribute to the development of
hepatic encephalopathy and coma and associated foetor hepaticus [Mitchell
et al 1999].
– In uremia, increased release of TMA from dietary precursors as a
consequence of bacterial overgrowth in the small intestine, coupled with
reduced renal clearance of TMA, can result in trimethylaminuria. The
elevated blood concentration of TMA may contribute to nephritic neurologic
conditions.
Other causes of unpleasant body odor fall into two categories:
• Those not involving an increase of trimethylamine in the urine, including poor
hygiene, gingivitis, and cases of blood-borne halitosis [Tangerman 2002] resulting
from malodorous compounds other than trimethylamine. Another condition in this
category is the rare metabolic disorder dimethylglycinuria, caused by dimethylglycine
dehydrogenase deficiency [Binzak et al 2001]. Such conditions are distinguished by
low urinary TMA and a normal urinary TMA/TMA N-oxide ratio.
• Those resulting in an increase of trimethylamine in the urine, including urinary
tract infections, bacterial vaginosis, advanced liver or kidney disease, and cervical
cancer. In these cases, the TMA/TMA N-oxide ratio is normal, but affected individuals
have large amounts of TMA in the urine. In contrast, the primary genetic form of
trimethylaminuria, caused by FMO3 deficiency, is characterized by a high ratio of
TMA/TMA N-oxide in the urine.
Management
Evaluations Following Initial Diagnosis
Urinary ratio of TMA N-oxide to total TMA on a normal diet indicates the severity of disease
in an individual diagnosed with trimethylaminuria:
• Ratios of 70%-89% are classified as "mild."
• Ratios lower than 70% are classified as severe.
The general rule is that the lower the ratio the more severe the disorder.
Treatment of Manifestations
Strategies for the treatment of trimethylaminuria have been discussed in detail [Cashman et al
2003] and "best-practice" guidelines have been summarized [Chalmers et al 2006].
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Restriction of dietary trimethylamine and its precursors.  In some cases the disorder can
be successfully managed by dietary restriction of precursors of trimethylamine. This is
particularly true of "mild" or moderate forms of the disorder. Affected individuals respond
differently to different forms of dietary restriction; thus, urinary excretion of trimethylamine
and trimethylamine N-oxide should be monitored to identify the most effective dietary regimen
for an individual.
• Choline.  One of the most important dietary sources of trimethylamine is choline.
Dietary choline is absorbed through the small intestine; however, when the absorptive
capacity of the small intestine is overloaded, gut bacteria metabolize choline into
trimethylamine, which is readily absorbed into the blood stream.
Foods rich in choline include eggs, liver, kidney, peas, beans, peanuts, soya products,
and brassicas (Brussels sprouts, broccoli, cabbage, cauliflower), including rapeseed
products such as oil and flour. Nutritionally balanced, choline-restricted diets suitable
for the treatment of trimethylaminuria have been developed [Busby et al 2004].
Affected individuals should avoid lecithin (an important dietary source of choline)
and lecithin-containing fish oil supplements.
• Trimethylamine N-oxide.  Affected individuals should avoid eating seafood (fish,
cephalopods, and crustaceans) because of its high content of trimethylamine N-oxide,
which is reduced to trimethylamine in the human gut. Babies with trimethylaminuria
who are breastfed after their mothers have eaten seafood may develop a fishy odor.
Note: Freshwater fish have a lower content of trimethylamine N-oxide and thus are
not a problem.
• Other.  Milk obtained from wheat-fed cows may have significant amounts of
trimethylamine and thus should be avoided.
In addition to being a source of trimethylamine precursors, brassicas (Brussels
sprouts, broccoli, cabbage, and cauliflower) contain indoles, which may inhibit FMO3
enzyme activity and thus increase urinary excretion of trimethylamine [Cashman et
al 1999]. Intake of such vegetables should be restricted.
Use of acid soaps and body lotions.  Trimethylamine is a strong base (pKa 9.8). Thus, at pH
6.0, less than 0.02% of trimethylamine exists as the volatile free base. The use of soaps and
body lotions with a pH close to that of normal skin (pH 5.5-6.5) helps retain secreted
trimethylamine in a less volatile salt form that can be removed by washing.
Sequestering of trimethylamine produced in the gut.  When taken as dietary supplements,
activated charcoal (750 mg twice daily for ten days) and copper chlorophyllin (60 mg three
times a day after meals for three weeks) decrease the concentration of free trimethylamine in
the urine [Yamazaki et al 2004].
Suppression of intestinal production of trimethylamine.  A short course of antibiotics to
modulate or reduce the activity of gut microflora, and thus suppress the production of
trimethylamine, is effective in some cases [Fraser-Andrews et al 2003, Chalmers et al 2006].
Such treatment may be useful when dietary restriction needs to be relaxed (e.g., for important
social occasions), or when trimethylamine production appears to increase (e.g., during
menstruation, infection, emotional upset, stress, or exercise). Three antibiotics with different
target organisms have been used: metronidazole, amoxicillin, and neomycin. Neomycin
appears to be the most effective in preventing formation of trimethylamine from choline
[Chalmers et al 2006].
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Laxatives, such as lactulose, to decrease intestinal transit time may also reduce the amount of
trimethylamine produced in the gut.
Enhancement of residual FMO3 enzyme activity.  Supplements of riboflavin, a precursor
of the FAD prosthetic group of FMOs, may help maximize residual FMO3 enzyme activity.
Recommended intake is 30-40 mg, three to five times per day, with food. Children given
riboflavin should be monitored closely because excessive amounts may cause gastrointestinal
distress.
Counseling.  Affected individuals and their families benefit from counseling. Realization that
the problem is the result of a recognized medical condition may help. As well as receiving
dietary advice, affected individuals should be advised that the condition may be exacerbated
during menstruation and by factors that promote sweating, such as fever, exercise, stress, and
emotional upsets.
Prevention of Primary Manifestations
See Treatment of Manifestations.
Prevention of Secondary Complications
Because choline is essential in the fetus and in young infants for nerve and brain development,
it should not be over-restricted in infants, children, and pregnant or lactating women. Large
amounts of choline are transferred to the fetus via the placenta and to the newborn infant via
the mother's milk, thus potentially depleting maternal choline reserves. Dietary restriction of
choline increases the requirement for folate, a methyl donor.
Dietary regimens should be planned and monitored to ensure that the daily intake of choline
and folate meet recommendations for the age and sex of the individual [Institute of Medicine,
National Academy of Sciences USA 1998; Cashman et al 2003]. For adults, adequate daily
intake of choline is 550 mg for males and 425 mg for females.
Agents/Circumstances to Avoid
The following should be avoided:
• Foods with a high content of precursors of trimethylamine or inhibitors of FMO3
enzyme activity, including seafood (fish, cephalopods, and crustaceans), eggs, offal,
legumes, brassicas, and soya products; avoid or eat in moderation
• Food supplements and "health" foods that contain high doses of the trimethylamine
precursors choline and lecithin
• Drugs that are metabolized by the FMO3 enzyme. These compete for residual FMO3
activity. As well as exacerbating the condition, reduced metabolism of the drug may
cause adverse effects.
• Factors that promote sweating, such as exercise, stress, and emotional upsets
Testing of Relatives at Risk
Biochemical testing of sibs is appropriate to identify those who are affected and will benefit
from early treatment of manifestations. If the causative mutation(s) in the family has been
identified, at-risk relatives can be offered molecular genetic testing.
See Genetic Counseling for issues related to testing of at-risk relatives for genetic counseling
purposes.
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Therapies Under Investigation
Search ClinicalTrials.gov for access to information on clinical studies for a wide range of
diseases and conditions. Note: There may not be clinical trials for this disorder.
Other
Genetics clinics are a source of information for individuals and families regarding the natural
history, treatment, mode of inheritance, and genetic risks to other family members as well as
information about available consumer-oriented resources. See the GeneTests Clinic
Directory.
Support groups have been established for individuals and families to provide information,
support, and contact with other affected individuals. The Resources section may include
disease-specific and/or umbrella support organizations.
Genetic Counseling
Genetic counseling is the process of providing individuals and families with information on
the nature, inheritance, and implications of genetic disorders to help them make informed
medical and personal decisions. The following section deals with genetic risk assessment and
the use of family history and genetic testing to clarify genetic status for family members. This
section is not meant to address all personal, cultural, or ethical issues that individuals may
face or to substitute for consultation with a genetics professional. To find a genetics or prenatal
diagnosis clinic, see the GeneTests Clinic Directory. —ED.
Mode of Inheritance
Trimethylaminuria is inherited in an autosomal recessive manner.
Risk to Family Members
Parents of a proband
• The parents of an affected individual are obligate heterozygotes and therefore carry
one mutant allele.
• Heterozygotes (carriers) are asymptomatic.
Sibs of a proband
• At conception, each sib of an affected individual has a 25% chance of being affected,
a 50% chance of being an asymptomatic carrier, and a 25% chance of being unaffected
and not a carrier.
• Once an at-risk sib is known to be unaffected, the risk of his/her being a carrier is 2/3.
• Heterozygotes (carriers) are asymptomatic.
Offspring of a proband.  The offspring of an individual with trimethylaminuria are obligate
heterozygotes (carriers) for a disease-causing mutation.
Other family members of a proband.  Each sib of the proband's parents is at a 50% risk of
being a carrier.
Carrier Detection
Molecular genetic testing.  Carrier testing for at-risk family members is available once the
mutations have been identified in the family.
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Biochemical genetic testing.  Carrier status can be clarified using biochemical testing by
analyzing the concentration and ratio of trimethylamine and trimethylamine N-oxide in urine
after an oral challenge of trimethylamine (600 mg).
Related Genetic Counseling Issues
See Management: Treatment of Manifestations for information on testing at-risk relatives for
the purpose of early diagnosis and treatment.
Family planning.  The optimal time for determination of genetic risk and clarification of carrier
status is before pregnancy. It is appropriate to offer genetic counseling (including discussion
of potential risks to offspring and reproductive options) to young adults who are affected.
DNA banking.  DNA banking is the storage of DNA (typically extracted from white blood
cells) for possible future use. Because it is likely that testing methodology and our
understanding of genes, mutations, and diseases will improve in the future, consideration
should be given to banking DNA of affected individuals. DNA banking is particularly relevant
when the sensitivity of currently availahble testing is less than 100%. See for a
list of laboratories offering DNA banking.
Prenatal Testing
No laboratories offering molecular genetic testing for prenatal diagnosis of trimethylaminuria
are listed in the GeneTests Laboratory Directory. However, prenatal testing may be available
for families in which the disease-causing mutations have been identified. For laboratories
offering custom prenatal testing, see .
Requests for prenatal testing for conditions such as trimethylaminuria that do not affect intellect
or life span and have treatment available are not common. Differences in perspective may exist
among medical professionals and within families regarding the use of prenatal testing,
particularly if the testing is being considered for the purpose of pregnancy termination rather
than early diagnosis. Although most centers would consider decisions about prenatal testing
to be the choice of the parents, discussion of these issues is appropriate.
Preimplantation genetic diagnosis (PGD) may be available for families in which the disease-
causing mutations have been identified. For laboratories offering PGD, see .
Molecular Genetics
Information in the Molecular Genetics tables may differ from that in the text; tables may contain
more recent information. —ED.
Table A. Molecular Genetics of Trimethylaminuria
Gene Symbol Chromosomal Locus Protein Name
FMO3 1q24.3 Flavin-containing monooxygenase 3
Data are compiled from the following standard references: Gene symbol from HUGO; chromosomal locus, locus name, critical region,
complementation group from OMIM; protein name from Swiss-Prot.
Table B. OMIM Entries for Trimethylaminuria
 136132 FLAVIN-CONTAINING MONOOXYGENASE 3; FMO3
 602079 TRIMETHYLAMINURIA; TMAU
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Table C. Genomic Databases for Trimethylaminuria
Gene Symbol Locus Specific Entrez Gene HGMD GeneCards GDB GenAtlas
FMO3 FMO3 2328 (MIM No. 136132) FMO3 FMO3 135136 FMO3
For a description of the genomic databases listed, click here.
Note:  HGMD requires registration.
Normal allelic variants: The FMO3 gene spans 27 kb and contains nine exons, of which exon
1 is non-coding [Dolphin, Riley et al 1997]. The gene encodes a mature mRNA of 2.1 kb.
Fifteen different nonsynonymous single-nucleotide variants in the gene have been identified
[Phillips et al, in press]. Individually, with the exception of p.Asn61Lys and p.Leu360Pro,
these have little or no effect on protein function. However, some nonsynonymous variants
when present in cis configuration in the homozygous state can cause a "mild" phenotype.
Pathologic allelic variants: At least 30 distinct mutations have been reported [Hernandez et
al 2003] (see Table 3) (pdf). Most are missense mutations, but nonsense mutations, small (1-
or 2-bp) deletions and one large (12.2 kb) deletion have been reported. The most common
mutations identified to date are p.Pro153Leu [Dolphin, Janmohamed et al 1997] and
p.Glu305X [Treacy et al 1998]. Some mutations impair assembly of the holoenzyme (i.e., the
ability of the apoprotein to bind FAD) whereas others affect kinetic competency [Yeung et al
2007].
Some nonsynonymous variants, when present in cis configuration (e.g., p.Glu158Lys and
p.Glu308Gly) can result in a moderate decrease in enzyme activity [Koukouritaki & Hines
2005; Phillips et al, in press]. When present in the homozygous state, they may cause mild or
transient trimethylaminuria, particularly in infants and young children, who have low
expression of FMO3. The mutation p.Asn61Lys results in a severe reduction in FMO3 activity
[Koukouritaki et al 2007] and thus is likely to cause primary genetic trimethylaminuria;
however, no affected individuals with this mutation have been identified. The mutation
p.Leu360Pro is the only variant to result in an increase in enzyme activity [Lattard et al
2003]. See Table 2.
Table 2. FMO3 Pathologic Allelic Variants Discussed in This GeneReview
Class of Variant Allele DNA Nucleotide Change Protein Amino Acid Change Reference Sequence
"Mild" variants that affect enzyme activity  1
c.472G>A p.Glu158Lys
NP_008825.4
NM_006894.4
c.923A>G p.Glu308Gly
c.1079T>C p.Leu360Pro
Pathologic
c.458C>T p.Pro153Leu
c.913G>T p.Glu305X
See Quick Reference for an explanation of nomenclature. GeneReviews follows the standard naming conventions of the Human Genome Variation
Society (www.hgvs.org). 
1. See details in paragraph preceding table.
Normal gene product: The normal product of the FMO3 gene is the protein flavin-containing
monooxygenase 3 (FMO3), which has a molecular mass of 60 kd and contains 532 amino acid
residues. FMO3 is located in the membranes of the endoplasmic reticulum. The enzyme
catalyzes the oxygenation of a wide range of foreign chemicals. At the site of oxygenation
preferred substrates contain a soft nucleophile – typically a nitrogen, sulfur, phosphorous, or
selenium atom [Krueger & Williams 2005]. One of the reactions catalyzed by FMO3 is the
oxygenation of the odorous tertiary amine trimethylamine to its non-odorous N-oxide.
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Abnormal gene product: The mutations that cause severe trimethylaminuria essentially
abolish FMO3 activity and are thus "null" mutations. The mutation p.Asn61Ser, however,
abolishes N-oxygenation of trimethylamine and thus causes trimethylaminuria but has no effect
on the S-oxygenation of methimazole [Dolphin et al 2000].
Resources
GeneReviews provides information about selected national organizations and resources for
the benefit of the reader. GeneReviews is not responsible for information provided by other
organizations. -ED.
National Human Genome Research Institute
Learning About Trimethylaminuria
National Library of Medicine Genetics Home Reference
Trimethylaminuria
Trimethylaminuria Foundation
PO Box 3361 
Grand Central Station 
New York NY 10163-3361 
Phone: 212-300-4168 
Email: thetfnetwk@aol.com
Children Living with Inherited Metabolic Diseases (CLIMB)
Climb Building 
176 Nantwich Road 
Crewe CW2 6BG 
United Kingdom 
Phone: 0800 652 3181 (toll free) 
Email: info.svcs@climb.org.uk 
www.climb.org.uk
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Medical Genetic Searches: A specialized PubMed search designed for clinicians that is located
on the PubMed Clinical Queries page. 
Published Statements and Policies Regarding Genetic Testing
No specific guidelines regarding genetic testing for this disorder have been developed.
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